This is not the most recent version of the article. View current version (16 JUL 2008)

Intervention Protocol

Antithrombin III for critically ill patients

  1. A Afshari,
  2. AM Møller,
  3. J Wetterslev

Editorial Group: Cochrane Anaesthesia Group

Published Online: 20 JUL 2005

DOI: 10.1002/14651858.CD005370

How to Cite

Afshari A, Møller AM, Wetterslev J. Antithrombin III for critically ill patients (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005370. DOI: 10.1002/14651858.CD005370.

Author Information

*Dr Arash Afshari, Resident, Department of anaesthesiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, 2100 Ø, DENMARK. arriba_a@yahoo.dk.

Publication History

  1. Publication Status: Unchanged
  2. Published Online: 20 JUL 2005

SEARCH

This is not the most recent version of the article. View current version (16 JUL 2008)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We aim to assess the efficacy and side effects of antithrombin III (AT III) treatment among critically ill patients. We aim to assess whether the efficacy and side effects differ in different subgroups (severe sepsis or septic shock or DIC, obstetrics, trauma, paediatric and heparin administration).

We will assess the efficacy of AT III by testing the following primary hypotheses:
(1) AT III reduces the incidence of death;
(2) AT III reduces the incidence of any other adverse outcome (adjusted for mortality);
(3) AT III reduces severity of disease among critically ill patients;
(4) AT III improves the quality of life among critically ill patients.

We will assess the efficacy of AT III by testing the following secondary hypotheses:
(1) AT III increases the incidence of bleeding episodes;
(2) AT III decreases the length of stay in the intensive care unit (adjusted for mortality);
(3) AT III decreases the length of stay in hospital (adjusted for mortality).

We will assess how the efficacy of AT III varies between various subgroups by testing the following hypotheses:
(1) the effect (see primary and secondary hypotheses) of AT III is different in the following subgroups; participants given heparin, participants not given heparin;
(2) the effect (see primary and secondary hypotheses) of AT III varies in participants given AT III depending on the duration of drug administration ( up to one week; more than one week); this criterion is based on our knowledge of the administration regimens proposed by various authors;
(3) the effect (see primary and secondary hypotheses) of AT III is different in the following subgroups:
(a) severe infection (sepsis or septic shock or DIC);
(b) trauma;
(c) obstetrics (eclampsia or preeclampsia or DIC);
(d) paediatrics (age below 18 as inclusion criteria);

We will include only entire trials for subgroup analysis in 'Objectives' 3a to 3d. We will not perform pooling of subgroups from different studies. We will only select trauma, obstetric and paediatric studies in which patients are randomized to either a treatment or control group (placebo or no treatment).